Alto Neuroscience (ANRO) & Its Rivals Head to Head Analysis

Alto Neuroscience (NYSE:ANRO) is one of 1,075 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Alto Neuroscience to similar companies based on the strength of its valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Institutional and Insider Ownership

44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Alto Neuroscience has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Alto Neuroscience’s peers have a beta of 3.84, suggesting that their average stock price is 284% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Alto Neuroscience and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	0	3	4	0	2.57
Alto Neuroscience Competitors	8574	22505	50735	1385	2.54

Alto Neuroscience presently has a consensus price target of $15.40, suggesting a potential upside of 529.86%. As a group, “Pharmaceutical preparations” companies have a potential upside of 213.75%. Given Alto Neuroscience’s stronger consensus rating and higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than its peers.

Earnings and Valuation

This table compares Alto Neuroscience and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alto Neuroscience	N/A	-$36.31 million	-0.96
Alto Neuroscience Competitors	$9.89 billion	$136.37 million	-5.85

Alto Neuroscience’s peers have higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Alto Neuroscience and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-49.28%	-33.52%
Alto Neuroscience Competitors	-3,399.87%	-235.11%	-32.77%

Summary

Alto Neuroscience peers beat Alto Neuroscience on 8 of the 13 factors compared.

About Alto Neuroscience

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.